Sanofi has announced an investment of more than €600 m in a vaccine manufacturing facility at its existing site in Toronto, Canada. The investment will provide additional antigen and filling capacity for the company’s Fluzone high-dose Quadrivalent influenza vaccine, helping to increase supply availability in Canada, the United States and Europe.
“As a leading vaccines Company, we continuously look ahead to address the fast-growing demand for those influenza vaccines that have demonstrated clinical superiority against standard-dose vaccines. Fluzone High-Dose provides a long-term competitive advantage and this new investment will ensure more seniors around the world are better protected against influenza and its complications. In addition, it will be a key resource to assist against future pandemics,” said Paul Hudson, CEO, Sanofi. “We welcome the ongoing partnership with the Canadian authorities, who supported us to make today’s great news a reality; this will make the country, which has a strong legacy in vaccines research and development, one of our key hubs in our effort to protect and improve human health across the globe.”
François-Philippe Champagne, Minister of Innovation, Science and Industry said: “Today’s announcement demonstrates Canada’s ability to attract foreign investment and to develop facilities with made-in-Canada solutions. This once-in-a-generation investment shows our government’s commitment to rebuilding Canada’s domestic biomanufacturing sector, focusing on both short-term strategic solutions and a long‑term vision. By investing in this project, our government is helping to keep expertise in Canada, creating and maintaining highly skilled jobs, and securing the health and safety of Canadians. By fostering an environment where companies can invest and grow, leading life sciences firms like Sanofi are increasingly looking to this country to establish their manufacturing facilities.”
Sanofi expects the facility to be operational in 2026, following design, construction, testing and qualification of the facility and equipment.
Fluzone High-Dose Quadrivalent influenza vaccine is currently manufactured exclusively by Sanofi Pasteur, Sanofi’s vaccines global business unit, at its Swiftwater, Pennsylvania Site in the United States. The unit has been continuously investing in expanding manufacturing capabilities for influenza vaccines. Two additional facilities in Swiftwater, Pa., US and Val-de-Reuil, France will start operations in the coming years.